Zymergen Investors Can't Beat Suit Over Pre-IPO Statements

By Sydney Price

Three of the largest investors of biotechnology company Zymergen cannot escape a suit accusing them of misleading shareholders ahead of the company's initial public offering by approving misstatements about the company's commercial product pipeline.

 Order attached | Read full article » | Save to favorites »